2005, Number 06
PDF size: 92.46 Kb.
ABSTRACTPolycystic ovary is characterized by anovulation, hyperandrogenemia and insulin resistance. Hyperinsulinemia is known to be associated with an increase in cardiovascular risk and the development of diabetes mellitus. The finding that insulin resistance has important implications in the pathogenesis of polycystic ovarian disease has elicit the concept of a therapeutic approach of insulin-sensitizing drugs. Last decade multiple clinical trials about these drugs and upon genesis of polycystic ovary were designed; hence there is now sufficient evidence in the literature to support its clinical use. The management of polycystic ovary includes short-term objectives, such as treatment of infertility and control of androgen excess, as well as long-term considerations, such as prevention of endometrial cancer and management of dysmetabolic syndrome with its associated risk for developing type 2 diabetes and cardiovascular disease. The present review justifies the rationale use of insulin-sensitizing drugs in order to treat both short-term and long-term issues regarding polycystic ovarian disease.
Centeno A, Hernández I, Mendoza R, et al. Ovarios poliquísticos: expresión clínica y bioquímica. Ginecol Obstet Mex 2003;71:253-8.
De Leo V, La Marca A, Petraglia F. Insulin-lowering agents in the management of polycystic ovary syndrome. Endocrin Rev 2003;24:633-67.
Yann R, Frederique D, Loic G, et al. Ultrasound assessment of ovarian stroma hypertrophy in hyperandrogenism and ovulation disorders: visual analysis versus computarized quantification. Fertil Steril 1995;64:307-12.
Taylor A, McCourt B, Martin K. Determinants of abnormal gonadotropin secretion in clinically defined women with polycystic ovary syndrome. J Clin Endocrinol Metab 1997;82:2248-53.
Apter D, Butzow T, Laughlin G. Metabolic features of polycystic ovary syndrome are found in adolescent girls with hyperandrogenism. J Clin Endocrinol Metab 1995;80:2966-71.
Nelson V, Qin K, Rosenfield R, Wood J, et al. The biochemical basis for increased testosterone production in theca cells propagated from patients with polycystic ovary syndrome. J Clin Endocrinol Metab 2001;86:5925-33.
Wickenheisser J, Quinn P, Nelson V, et al. Differential activity of the cytochrome P450 17ahydroxilase and steroidogenic acute regulatory protein gene promoters in normal and polycystic ovary syndrome theca cells. J Clin Endocrinol Metab 2000;85:2304-11.
Elting M, Korsen T, Rekers-Mombarg L, et al. Women with polycystic ovary syndrome gain regular menstrual cycles when ageing. Hum Reprod 2000;15:24-28.
Wang J, Davies M, Norman R. Polycystic ovary syndrome and the risk of spontaneous abortion following assisted reproductive technology treatment. Hum Reprod 2001;16:2606-9.
Holte J, Gennarelli G, Wide L, et al. High prevalence of polycystic and associated clinical, endocrine, and metabolic features in women with previous gestational diabetes mellitus. J Clin Endocrinol Metab 1998;83:1143-50.
Rajkhowa M, Neary R, Kumpatla P. Altered composition of high density lipoproteins in women with the polycystic ovary syndrome. J Clin Endocrinol Metab 1997;82:3389-94.
Atiomo W, Bates S, Condon J, et al. The plasminogen activator system in women with polycystic ovary syndrome Fertil Steril 1998;69:236-41.
Cheung A. Ultrasound and menstrual history in predicting endometrial hyperplasia in polycystic ovary syndrome. Obstet Gynecol 2001;98:325-31.
Reaven G. Role of insulin resistance in human disease. Diabetes 1988;37:1595-607.
Pellicer A, Simón C. Cuadernos de medicina reproductiva. Hiperandrogenismos. 1ª ed. Madrid: Panamericana,1996.
Katz A, Nambi S, Mather K, et al. Quantitative insulin sensitivity in humans. J Clin Endocrinol Metab 2000;85:2402-10.
Barbieri R. Induction of ovulation in infertile women with hyperandrogenism and insulin resistance. Am J Obstet Gynecol 2000;183:1412-8.
Ching W, Yap C, Sian A. Clinical management of PCOS. Acta Obstet Gynaecol Scand 2001;80:689-96.
Ibañez L, Potau N, Ferrer A, et al. Anovulation in eumenorrheic, nonobese adolescent girls born small for gestational age: insulin sensitization induces ovulation, increases lean body mass, and reduces abdominal fat excess, dyslipidemia, and subclinical hyperandrogenism. J Clin Endocrinol Metab 2002;87:5702-5.
Costello M, Eden J. A systematic review of the reproductive system effects of metformin in patients with polycystic ovary syndrome. Fertil Steril 2003;79:1-13.
Ibañez L, Valls C, Ferrer A, et al. Sensitization to insulin induces ovulation in nonobese adolescents with anovulatory hyperandrogenism. J Clin Endocrinol Metab 2001;86:3595-8.
Nestler J, Jakubowicz D, Evans W, et al. Effects of metformin on spontaneous and clomiphene-induced ovulation in the polycystic ovary syndrome. N Engl J Med 1998;338:1876-80.
Heard M, Pierce A, Carson S, et al. Pregnancies following use of metformin for ovulation induction in patients with polycystic ovary syndrome. Fertil Steril 2002;77:669-73.